ArticleThe Journal of allergy and clinical immunology2015
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
Article in The Journal of allergy and clinical immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 140 citations in OpenAlex.
- Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.The Journal of allergy and clinical immunology · 2018Trial
- PreDicta chip-based high resolution diagnosis of rhinovirus-induced wheeze.Nature communications · 2018Trial
- Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement.Nature communications · 2018Trial
- Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.EBioMedicine · 2016Trial
- Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients.The Journal of allergy and clinical immunology · 2015Trial
- Molecular Biomarkers in IgE Immunoassays Used for Grass Pollen Allergy Diagnosis in European Clinical Settings.International journal of molecular sciences · 2026Review
- Recombinant Hypoallergenic Cat Allergy Vaccines.Allergy · 2025Article
- B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in a Blomia tropicalis-murine model.Respiratory research · 2025Article
- B-cell epitope prediction for developing allergy vaccines and their companion immunodiagnostics.Frontiers in immunology · 2025Article
- Role of allergen immunotherapy and biologics in allergic diseases.Current opinion in immunology · 2024Review
- Article
- Sensitization patterns to Poaceae pollen indicates a hierarchy in allergens and a lead of tropical grasses.Clinical and translational allergy · 2023Article
- Peptide immunotherapy for aeroallergens.Allergy and asthma proceedings · 2023Article
- Allergen-specific immunotherapy by recombinant Der P1 allergen-derived peptide-based vaccine in an allergic mouse model.Immunity, inflammation and disease · 2023Article
- Computational Vaccine Design for Common Allergens.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Mechanism and clinical evidence of immunotherapy in allergic rhinitis.Frontiers in allergy · 2023Review
- Identification of Epitopes on Rhinovirus 89 Capsid Proteins Capable of Inducing Neutralizing Antibodies.International journal of molecular sciences · 2022Article
- Proteomics for Development of Food Allergy Vaccines.Methods in molecular biology (Clifton, N.J.) · 2022Article
- On the role of allergen-specific IgG subclasses for blocking human basophil activation.Frontiers in immunology · 2022Article
- Linear Epitope Binding Patterns of Grass Pollen-Specific Antibodies in Allergy and in Response to Allergen-Specific Immunotherapy.Frontiers in allergy · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundGrass pollen is one of the most important sources of respiratory allergies worldwide.
objectiveThis study describes the development of a grass pollen allergy vaccine based on recombinant hypoallergenic derivatives of the major timothy grass pollen allergens Phl p 1, Phl p 2, Phl p 5, and Phl p 6 by using a peptide-carrier approach.
methodsFusion proteins consisting of nonallergenic peptides from the 4 major timothy grass pollen allergens and the PreS protein from hepatitis B virus as a carrier were expressed in Escherichia coli and purified by means of chromatography. Recombinant PreS fusion proteins were tested for allergenic activity and T-cell activation by means of IgE serology, basophil activation testing, T-cell proliferation assays, and xMAP Luminex technology in patients with grass pollen allergy. Rabbits were immunized with PreS fusion proteins to characterize their immunogenicity.
resultsTen hypoallergenic PreS fusion proteins were constructed, expressed, and purified. According to immunogenicity and induction of allergen-specific blocking IgG antibodies, 4 hypoallergenic fusion proteins (BM321, BM322, BM325, and BM326) representing Phl p 1, Phl p 2, Phl p 5, and Phl p 6 were included as components in the vaccine termed BM32. BM321, BM322, BM325, and BM326 showed almost completely abolished allergenic activity and induced significantly reduced T-cell proliferation and release of proinflammatory cytokines in patients' PBMCs compared with grass pollen allergens. On immunization, they induced allergen-specific IgG antibodies, which inhibited patients' IgE binding to all 4 major allergens of grass pollen, as well as allergen-induced basophil activation.
conclusionA recombinant hypoallergenic grass pollen allergy vaccine (BM32) consisting of 4 recombinant PreS-fused grass pollen allergen peptides was developed for safe immunotherapy of grass pollen allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.